Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX 03:32:23 2024-06-12 pm EDT 5-day change 1st Jan Change
299.6 USD -0.35% Intraday chart for Amgen Inc. -2.20% +4.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Transcript : Amgen Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM
Amgen Says Phase 3 Trial of Potential Autoimmune Disease Treatment Meets Endpoints MT
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD DJ
Amgen's drug meets main goal in late-stage study for rare disease RE
Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd) CI
Amgen Inc. Appoints Dr. Mary E. Klotman as Director CI
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment RE
Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval DJ
Weight-loss drug forecasts jump to $150 billion as supply grows RE
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT
Transcript : Amgen Inc. - Special Call
HSBC Adjusts Price Target on Amgen to $356 From $322 MT
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results MT
Amgen Announces the Results of the Phase 2a COURSE Trial Evaluating Tezspire® (Tezepelumab-Ekko) in People with Moderate to Very Severe Chronic Obstructive Pulmonary Disease CI
US FDA approves Amgen drug for small cell lung cancer RE
FDA Approves Amgen's IMDELLTRA?? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer CI
Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment DJ
Amgen's Imdelltra Gets US FDA Accelerated Approval for Drug to Treat Extensive Stage Small Cell Lung Cancer MT
US FDA approves Amgen drug for small cell lung cancer, Bloomberg News reports RE
Transcript : Amgen Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating MT
ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... Our Logo
Chart Amgen Inc.
More charts
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
300.7 USD
Average target price
316.3 USD
Spread / Average Target
+5.18%
Consensus
  1. Stock Market
  2. Equities
  3. AMGN Stock
  4. News Amgen Inc.
  5. Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition